Remove tag cancer-control
article thumbnail

Cannabinoids receptors: popular preclinical target but banned in 137 countries

Pharmaceutical Technology

Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. However, at the federal level, cannabinoids remain illegal under the Controlled Substances Act. This is closely followed by CB2 receptors in second place.

article thumbnail

Epigenetics discovery could lead to new class of cancer drugs

Drug Discovery World

A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs. Epigenetics is still largely unexplored and referred to as the ‘dark matter’ of the genome.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds February 24, 2023: S2302 Pragmatica-Lung: New Directions for Decreasing Burden and Increasing Inclusion in NCTN Clinical Trials (Konstantin Dragnev, MD; Karen Reckamp, MD, MS)

Rethinking Clinical Trials

They are both approved and used widely in lung cancer, and combining two existing agents is logistically and clinically simpler. When we started working on this the discussions with NCI and FDA were about stripping away eligibility, we realized the population would be less controlled than previous studies.

article thumbnail

Immunocore’s Kimmtrak Gets FDA Approval as First Treatment for Rare Eye Cancer and First T Cell Receptor Therapeutic

XTalks

Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose. Related: Cancer Blood Test Developed by University of Oxford Researchers Can Detect Metastasis. In the control group, 82 percent of patients were given Merck’s Keytruda. months versus 16 months for patients in the control group.

article thumbnail

Leading innovators in peptide nano-particle conjugates for the pharmaceutical industry

Pharmaceutical Technology

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Antibody 130
article thumbnail

bluebird bio to split into oncology and gene therapy specialists

pharmaphorum

While bluebird has conducted pioneering work in gene therapy for blood disorders and in cancer cell therapy, products have been delayed by issues with filing data for the FDA. million price tag. Zynteglo is already in beta-thalassemia in Europe, where the company will seek to expand access despite its hefty $1.8

article thumbnail

Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer

Delveinsight

GRAIL and Quest collaborate for the cancer blood test. Cancer detection company GRAIL has announced a collaboration with Quest Diagnostics that sees Quest proffering phlebotomy services to bolster GRAIL’s multi-cancer early detection blood test Galleri. Brain organoids grown in the lab mimic infant’s brains.

DNA 52